English, Article edition: Cost Effectiveness of Representatives of Three Classes of Antidepressants Used in Major Depression in the UK Alan Lenox-Smith; Pete Conway; Chris Knight

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94872
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Effectiveness of Representatives of Three Classes of Antidepressants Used in Major Depression in the UK
Author
  • Alan Lenox-Smith
  • Pete Conway
  • Chris Knight
Physical Description
  • article
Notes
  • Objective: To estimate the cost effectiveness of representatives of three different classes of antidepressants used in major depression in the UK NHS. Design, patients and interventions: A decision-tree model for the treatment of major depression was constructed by interviewing UK GPs and psychiatrists (as part of a Delphi panel). An important part of the tree was that patients in primary care were treated until remission (pre-morbid state). Three classes of antidepressants (serotonin and noradrenaline reuptake inhibitors [SNRIs; venlafaxine], selective serotonin reuptake inhibitors [SSRIs; fluoxetine, paroxetine and fluvoxamine] and tricyclic antidepressants [TCAs; amitriptyline]) were compared by populating the tree with clinical success rates determined by a meta-analysis and a clinical trial. Where there were insufficient data from clinical trials a Delphi panel was used. Costs within the tree were taken from UK data sources. Six-monthly costs and cost effectiveness were then calculated. Main outcome measures and results: Treatment costs for 6 months were Lstg 1285 for venlafaxine, Lstg 1348 for SSRIs and Lstg 1385 for amitriptyline. Cost effectiveness as measured by cost per symptom-free day was Lstg 21 for venlafaxine, Lstg 26 for SSRIs and Lstg 32 for TCAs (2001 values). Incremental cost-effectiveness analyses showed a treatment strategy of using venlafaxine and switching if necessary to an SSRI was dominant over all other strategies considered. Sensitivity testing demonstrated that the cost of an SSRI could be reduced to 4 pence daily and amitriptyline to zero before the expected 6-monthly cost of venlafaxine ceased to be the lowest. Conclusion: The SNRI, venlafaxine, may be a cost-effective option compared with the SSRIs and TCAs when used as a first-line drug for depression in primary care in the UK. As this is a model, cost effectiveness can be suggested but not proven.
  • Amitriptyline, Cost-effectiveness, Depression, Serotonin-reuptake-inhibitors, Tricyclic-antidepressants, Venlafaxine
  • RePEc:wkh:phecon:v:22:y:2004:i:5:p:311-319
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment